Watson Pharma announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the proposed merger between Teva Pharma, and Barr Pharma. The closing of the product acquisition is contingent upon the consummation of Teva's merger with Barr.
The portfolio of products consists of 17 products, including 15 FDA-approved products and 2 development-stage products. Key products in the portfolio include:
Cyclosporine Capsules and Liquid
Desmopressin Acetate Tablets
Glipizide/Metformin HCl Tablets
Mirtazapine Orally Disintegrating Tablets
Metoclopramide HCl Tablets
Source: Watson press release Here
No comments:
Post a Comment